drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (allogeneic NK cells)
drug_description
Off-the-shelf, allogeneic cord blood–derived natural killer (NK) cell therapy that provides cytotoxic NK cells mediating CD16 (FcγRIIIa)–dependent ADCC against anti-CD20–opsonized B cells.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Natural Killer Cells
drug_category
CULTURED CELLS
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Off-the-shelf allogeneic cord blood–derived NK cells that, via CD16 (FcγRIIIa), mediate antibody-dependent cellular cytotoxicity against anti-CD20–opsonized B cells (with rituximab/obinutuzumab), with additional innate NK cytotoxicity and cytokine effects.
drug_name
AB-101 (AlloNK)
nct_id_drug_ref
NCT06265220